Skip to menu Skip to content Skip to footer

A phase 3 open-label study of the safety and efficacy of Adalimumab in subjects with moderate to severe Hidradenitis Suppurativa (2013-2016)

Experts

Professor Peter Soyer

Affiliate of Queensland Digital Health Centre
Queensland Digital Health Centre
Faculty of Health, Medicine and Behavioural Sciences
Professorial Research Fellow
Frazer Institute
Faculty of Health, Medicine and Behavioural Sciences
Peter Soyer
Peter Soyer